TrialCancer immunology, immunotherapy : CII2021

Pembrolizumab in advanced osteosarcoma: results of a single-arm, open-label, phase 2 trial.

Kjetil Boye et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.